vs
MESA LABORATORIES INC（MLAB）とRepay Holdings Corp（RPAY）の財務データ比較。上の社名をクリックして会社を切り替えられます
Repay Holdings Corpの直近四半期売上が大きい（$78.6M vs $65.1M、MESA LABORATORIES INCの約1.2倍）。MESA LABORATORIES INCの純利益率が高く（5.6% vs -178.3%、差は183.9%）。MESA LABORATORIES INCの前年同期比売上増加率が高い（3.6% vs 0.4%）。Repay Holdings Corpの直近四半期フリーキャッシュフローが多い（$23.2M vs $18.0M）。過去8四半期でMESA LABORATORIES INCの売上複合成長率が高い（5.1% vs -1.3%）
メサラボラトリーズ社は、品質管理、校正、モニタリング向け専門機器及び関連サービスの開発・製造・販売を事業としています。医療、製薬、食品飲料、産業衛生、環境試験分野を中心に、世界中の顧客の規制遵守と運用安全のニーズに応えています。
Repay Holdings Corpは北米を主要市場とする決済テクノロジー企業で、小売、医療、自動車サービス、電子商取引などの業種の企業向けに、クレジット・デビットカード決済処理、ACH送金、POSシステム連携を含む統合決済ソリューションを提供し、顧客の業務効率化を支援しています。
MLAB vs RPAY — 直接比較
損益計算書 — Q3 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $65.1M | $78.6M |
| 純利益 | $3.6M | $-140.1M |
| 粗利率 | 64.2% | 74.2% |
| 営業利益率 | 12.2% | -182.2% |
| 純利益率 | 5.6% | -178.3% |
| 売上前年比 | 3.6% | 0.4% |
| 純利益前年比 | 316.6% | -3304.1% |
| EPS（希薄化後） | $0.65 | $-1.68 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $65.1M | $78.6M | ||
| Q3 25 | $60.7M | $77.7M | ||
| Q2 25 | $59.5M | $75.6M | ||
| Q1 25 | $62.1M | $77.3M | ||
| Q4 24 | $62.8M | $78.3M | ||
| Q3 24 | $57.8M | $79.1M | ||
| Q2 24 | $58.2M | $74.9M | ||
| Q1 24 | $58.9M | $80.7M |
| Q4 25 | $3.6M | $-140.1M | ||
| Q3 25 | $2.5M | $-6.4M | ||
| Q2 25 | $4.7M | $-102.3M | ||
| Q1 25 | $-7.1M | $-7.9M | ||
| Q4 24 | $-1.7M | $-4.1M | ||
| Q3 24 | $3.4M | $3.2M | ||
| Q2 24 | $3.4M | $-4.1M | ||
| Q1 24 | $-254.6M | $-5.2M |
| Q4 25 | 64.2% | 74.2% | ||
| Q3 25 | 61.5% | 74.4% | ||
| Q2 25 | 62.0% | 75.7% | ||
| Q1 25 | 61.8% | 75.9% | ||
| Q4 24 | 63.3% | 76.3% | ||
| Q3 24 | 61.3% | 77.8% | ||
| Q2 24 | 64.0% | 78.2% | ||
| Q1 24 | 62.1% | 76.2% |
| Q4 25 | 12.2% | -182.2% | ||
| Q3 25 | 7.8% | -3.9% | ||
| Q2 25 | 5.1% | -138.7% | ||
| Q1 25 | 2.4% | -4.7% | ||
| Q4 24 | 9.2% | -1.5% | ||
| Q3 24 | 6.1% | -0.9% | ||
| Q2 24 | 9.6% | -4.6% | ||
| Q1 24 | -460.6% | -3.1% |
| Q4 25 | 5.6% | -178.3% | ||
| Q3 25 | 4.1% | -8.3% | ||
| Q2 25 | 8.0% | -135.2% | ||
| Q1 25 | -11.4% | -10.3% | ||
| Q4 24 | -2.7% | -5.3% | ||
| Q3 24 | 5.9% | 4.1% | ||
| Q2 24 | 5.8% | -5.4% | ||
| Q1 24 | -432.2% | -6.5% |
| Q4 25 | $0.65 | $-1.68 | ||
| Q3 25 | $0.45 | $-0.08 | ||
| Q2 25 | $0.85 | $-1.15 | ||
| Q1 25 | $-1.30 | $-0.09 | ||
| Q4 24 | $-0.31 | $-0.04 | ||
| Q3 24 | $0.63 | $0.03 | ||
| Q2 24 | $0.62 | $-0.04 | ||
| Q1 24 | $-47.26 | $-0.06 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $29.0M | $115.7M |
| 総負債低いほど良い | $68.4M | $280.1M |
| 株主資本純資産 | $186.7M | $484.4M |
| 総資産 | $434.8M | $1.2B |
| 負債/資本比率低いほどレバレッジが低い | 0.37× | 0.58× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $29.0M | $115.7M | ||
| Q3 25 | $20.4M | $95.7M | ||
| Q2 25 | $21.3M | $162.6M | ||
| Q1 25 | $27.3M | $165.5M | ||
| Q4 24 | $27.3M | $189.5M | ||
| Q3 24 | $24.3M | $168.7M | ||
| Q2 24 | $28.5M | $147.1M | ||
| Q1 24 | $28.2M | $128.3M |
| Q4 25 | $68.4M | $280.1M | ||
| Q3 25 | $69.4M | $279.5M | ||
| Q2 25 | $70.3M | $279.0M | ||
| Q1 25 | $71.3M | $497.6M | ||
| Q4 24 | $72.2M | $496.8M | ||
| Q3 24 | $73.1M | $496.2M | ||
| Q2 24 | $74.1M | $435.6M | ||
| Q1 24 | — | $434.9M |
| Q4 25 | $186.7M | $484.4M | ||
| Q3 25 | $178.5M | $616.9M | ||
| Q2 25 | $172.5M | $633.7M | ||
| Q1 25 | $159.8M | $755.7M | ||
| Q4 24 | $155.2M | $761.3M | ||
| Q3 24 | $161.5M | $754.7M | ||
| Q2 24 | $150.7M | $815.4M | ||
| Q1 24 | $145.4M | $813.8M |
| Q4 25 | $434.8M | $1.2B | ||
| Q3 25 | $430.4M | $1.3B | ||
| Q2 25 | $435.7M | $1.4B | ||
| Q1 25 | $433.3M | $1.5B | ||
| Q4 24 | $433.3M | $1.6B | ||
| Q3 24 | $454.1M | $1.6B | ||
| Q2 24 | $440.4M | $1.5B | ||
| Q1 24 | $446.8M | $1.5B |
| Q4 25 | 0.37× | 0.58× | ||
| Q3 25 | 0.39× | 0.45× | ||
| Q2 25 | 0.41× | 0.44× | ||
| Q1 25 | 0.45× | 0.66× | ||
| Q4 24 | 0.47× | 0.65× | ||
| Q3 24 | 0.45× | 0.66× | ||
| Q2 24 | 0.49× | 0.53× | ||
| Q1 24 | — | 0.53× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $18.8M | $23.3M |
| フリーキャッシュフロー営業CF - 設備投資 | $18.0M | $23.2M |
| FCFマージンFCF / 売上 | 27.7% | 29.6% |
| 設備投資強度設備投資 / 売上 | 1.1% | 0.1% |
| キャッシュ転換率営業CF / 純利益 | 5.17× | — |
| 直近12ヶ月FCF直近4四半期 | $37.9M | $90.7M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $18.8M | $23.3M | ||
| Q3 25 | $8.2M | $32.2M | ||
| Q2 25 | $1.9M | $33.1M | ||
| Q1 25 | $12.7M | $2.5M | ||
| Q4 24 | $18.1M | $34.3M | ||
| Q3 24 | $5.3M | $60.1M | ||
| Q2 24 | $10.7M | $31.0M | ||
| Q1 24 | $12.9M | $24.8M |
| Q4 25 | $18.0M | $23.2M | ||
| Q3 25 | $7.1M | $32.1M | ||
| Q2 25 | $884.0K | $33.0M | ||
| Q1 25 | $11.9M | $2.4M | ||
| Q4 24 | $17.3M | $34.0M | ||
| Q3 24 | $3.5M | $59.8M | ||
| Q2 24 | $9.9M | $30.5M | ||
| Q1 24 | $12.3M | $24.7M |
| Q4 25 | 27.7% | 29.6% | ||
| Q3 25 | 11.7% | 41.3% | ||
| Q2 25 | 1.5% | 43.6% | ||
| Q1 25 | 19.2% | 3.0% | ||
| Q4 24 | 27.6% | 43.5% | ||
| Q3 24 | 6.0% | 75.6% | ||
| Q2 24 | 16.9% | 40.7% | ||
| Q1 24 | 21.0% | 30.6% |
| Q4 25 | 1.1% | 0.1% | ||
| Q3 25 | 1.8% | 0.2% | ||
| Q2 25 | 1.7% | 0.1% | ||
| Q1 25 | 1.2% | 0.2% | ||
| Q4 24 | 1.3% | 0.3% | ||
| Q3 24 | 3.1% | 0.3% | ||
| Q2 24 | 1.5% | 0.6% | ||
| Q1 24 | 0.9% | 0.1% |
| Q4 25 | 5.17× | — | ||
| Q3 25 | 3.32× | — | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.54× | 18.52× | ||
| Q2 24 | 3.17× | — | ||
| Q1 24 | — | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
RPAY
| Sales Channel Directly To Consumer | $69.4M | 88% |
| Other | $6.8M | 9% |
| Sales Channel Through Intermediary | $2.3M | 3% |
